ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

les laboratoires servier - strontíumranelat - beinþynning, eftir tíðahvörf - lyf til að meðhöndla beinsjúkdóma - meðferð við alvarlegum beinþynningu hjá konum eftir tíðahvörf sem eru í mikilli hættu á beinbrotum til að draga úr hættu á brotum á hryggjarliðum og mjöðmum. meðferð alvarlega beinbrot í fullorðnir menn á jókst hættan á beinbrot. sú ákvörðun að mæla strontíumranelati ætti að vera byggt á mat á sjúkling er heild áhættu.

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

lyfjaver ehf. - pregabalinum inn - hart hylki - 150 mg

আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

lyfjaver ehf. - pregabalinum inn - hart hylki - 25 mg

ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - Æxlishemjandi lyf - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.